Home // University // News // Slideshow // Luxembourg Parkinson’s Study funded with an additional 6 million euros

Luxembourg Parkinson’s Study funded with an additional 6 million euros

twitter linkedin facebook google+ email this page
Published on Friday, 19 July 2019

The Luxembourg National Research Fund (FNR) has committed an additional 6 million euros to National Centre for Excellence in Research on Parkinson’s Disease (NCER-PD), paving the way for the second phase of this collaborative research programme.

The NCER-PD was established in 2015 as the first inter-institutional research programme of its kind in Luxembourg. It is a joint effort between five partners* uniting their complementary expertise in Parkinson’s disease. The FNR committed 8.3 million euros for the first four years of the research programme. At the end of this first funding period, the programme has been evaluated with outstanding scores by an international jury of experts. This paved the way for its second phase, which lasts until May 2023.    

NCER-PD aims to understand the mechanism of Parkinson’s disease to enable an earlier diagnosis and to develop better treatments for the patients.

Marc Schiltz, Secretary General of the FNR states: “The National Centre of Excellence in Research on Parkinson’s Disease is a wonderful example of how research in Luxembourg can achieve outstanding international visibility and at the same time produce a direct impact on healthcare, by bringing together patients, researchers, doctors, and healthcare professionals.”

A large-scale and unique research study

To achieve its objective, NCER-PD set itself an impressive goal: to include 800 Parkinson’s patients, hence almost all of the estimated 1000 people affected by this disease in Luxembourg, as well as having a similarly structured control group of 800 people without Parkinson’s. As of July 2019, this goal was nearly met, with some 1400 persons being part of the study.

The recruitment for 100 participants per group is still ongoing.

Patients and healthy men over 65 years of age are invited to join.

After four years only, the Luxembourg Parkinson’s Study belongs to the largest Parkinson’s cohorts worldwide. What makes the Luxembourgish cohort unique: all patients are being followed up annually over the years, giving the researchers unprecedented information about the disease’s progression.

Initial NCER-PD research projects that study the molecular content of the blood as well as microbial composition and function in the gut show differences between people with and without Parkinson’s disease. As a next step, these first promising results need to be evaluated for use in the clinic as diagnostic biomarkers.  

Patient empowerment as a key element

NCER-PD strives to already give an immediate return to the patients. Patient empowerment is hence a key element of the study. “Through communication campaigns and close collaboration with patient associations in Luxembourg and the Greater Region, we informed patients, but also the general public, about the disease, its treatment options and current state of research. This plays an important role in reducing stigmatisation of people with this chronic disease”, says Prof. Rejko Krüger, Coordinator of NCER-PD.

Over the last four years, NCER-PD has successfully worked together with doctors, psychologists, nurses, biomedical and computational scientists. By creating ParkinsonNet, an integrated care programme for Parkinson’s Disease based on a Dutch concept, multidisciplinary teams now also come to action in healthcare, for the sole benefit of the patients. Hopeful that these concepts could soon also be applied to other disease areas in Luxembourg, Krüger says: “The very positive development of NCER-PD is a great opportunity, as Luxembourg can serve as the testbed for the medicine of the future, for novel and more personalised therapies.” 

“The disease has changed my life,” says Corinne Trivaudey, a patient involved in the study. “Nevertheless, it was nearly a relief to hear a diagnosis from the neurologist, because I finally knew what I was suffering from. Medication treats only fifty percent of the effects of the disease. I relieve some effects by physical activities. I hope the study will receive enough patients and volunteers to continue.”

“I’m joining this call. We must overcome this disease together, not hide it, "said Gerard Zoller, Rotary club member and volunteer in the control group. “The tests are not painful or invasive for volunteers, and it's time well used. Do not hesitate to volunteer or encourage people around you to participate.”

Focus on patient stratification and therapies in the second phase

The second four-year funding period will mainly build upon the obtained findings and scientific results, with a focus on these developments:

  • It will focus on further stratification of the cohort. Patients will continue to be monitored annually, as the longitudinal data will be essential to study the progression of the disease and to find new biomarkers.
  • NCER-PD will create a sub-cohort based on genetic analysis. Patients that carry mutations in a gene called GBA have a higher risk for cognitive decline and falls compared to other Parkinson’s patients. They will undergo specific testing and personalised clinical trials on nerve cell cultures derived from their skin samples in a quest for new therapeutics.
  • NCER-PD will develop an “at-risk” cohort of people with REM sleep behaviour disorder. As a large percentage of people with this specific sleeping problem develop Parkinson’s disease in the future, the researchers believe that close monitoring of this cohort will give insights into the onset and development of the disease.                

“Parkinson’s disease is a very complex disease with many symptoms and manifestations. By studying subgroups of patients, as we have planned for NCER-PD’s second phase, one can better understand the underlying mechanisms and contribute to the development of tailored therapies”, concludes Prof. Krüger.

___

*NCER-PD is a collaborative research programme between the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg, the Luxembourg Institute of Health (LIH) and its Integrated Biobank of Luxembourg (IBBL), the Laboratoire National de Santé and the Centre Hospitalier de Luxembourg.